Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Takeda Pharmaceutical Company Limited (NYSE: TAK) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Takeda Pharmaceutical Company Limited (NYSE: TAK) concerning whether a series of statements by Takeda Pharmaceutical Company Limited regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 14, 2019, the Company forecast an unexpected operating loss for the current year, citing costs associated with the Company’s $59 billion purchase of Shire Plc.

Following this news, Takeda’s American depositary receipt price fell $1.57 per share, or 8.06%, to close at $17.92 on May 14, 2019.

Based in Tokyo, Japan, and founded in 1781 Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products.

If you purchased shares of Takeda Pharmaceutical Company Limited (NYSE: TAK) on or before May 14, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185